Quarterly report pursuant to Section 13 or 15(d)

CONDENSED INTERIM STATEMENTS OF OPERATIONS

v3.23.1
CONDENSED INTERIM STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
OPERATING EXPENSES    
Research and Development $ 1,015,583 $ 818,888
General and Administrative 1,887,374 1,851,250
TOTAL OPERATING EXPENSES 2,902,957 2,670,138
NET LOSS $ (2,902,957) $ (2,670,138)
LOSS PER SHARE    
Basic net loss per common share $ (0.25) $ (0.26)
Diluted net loss per common share $ (0.25) $ (0.26)
Weighted average common shares outstanding basic 11,639,395 10,232,843
Weighted average common shares outstanding diluted 11,639,395 10,232,843